0
Sign In  | Subscribe
3 April 2007, Vol 146, No. 7>
Summaries for Patients | 3 April 2007

Exenatide Therapy for Type 2 Diabetes FREE

[+] Article and Author Information

The summary below is from the full report titled “The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes. A Randomized Trial.” It is in the 3 April 2007 issue of Annals of Internal Medicine (volume 146, pages 477-485). The authors are B. Zinman, B.J. Hoogwerf, S. Durán García, D.R. Milton, J.M. Giaconia, D.D. Kim, M.E. Trautmann, and R.G. Brodows.


Ann Intern Med. 2007;146(7):I-18. doi:10.7326/0003-4819-146-7-200704030-00002
Text Size: A A A

What is the problem and what is known about it so far?

Doctors often prescribe drugs to help patients with type 2 diabetes control their blood sugar. They use a blood test (called hemoglobin A1c) to assess sugar control. In most cases, doctors should aim for optimal control of sugar levels (hemoglobin A1c values less than 7%), depending on several factors. Some patients need more than 1 drug to get their blood sugar levels under optimal control. Drugs that may be used include insulin, alpha-glucosidase inhibitors (acarbose and miglitol), biguanides (metformin), sulfonyureas (glipizide or glyburide), and thiazolidinediones (TZDs, such as rosiglitazone and pioglitazone). Exenatide is a new drug called an incretin mimetic. Few studies have assessed whether adding this drug to TZD treatment improves sugar control.

Why did the researchers do this particular study?

To see whether adding exenatide to TZD treatment improves blood sugar control in adults with type 2 diabetes.

Who was studied?

233 middle-aged adults with suboptimal glucose control despite TZD treatment. The patients' average hemoglobin A1c value was 7.9%.

How was the study done?

The researchers recruited patients from 49 sites in Canada, Spain, and the United States. Patients were randomly assigned to twice-daily injections under the skin of either exenatide or placebo for 16 weeks. All patients were taking TZD pills, and some also took metformin pills. The researchers tested patients' blood for glucose levels, weighed patients, and asked patients about side effects. The researchers, doctors, and patients did not know who got exenatide or placebo.

What did the researchers find?

Exenatide reduced hemoglobin A1c levels by about 0.98% and body weight by about 3 pounds more than placebo. More patients who received exenatide than patients who received placebo had nausea (40% vs. 15%) or vomiting (13% vs. 1%).

What were the limitations of the study?

Treatment duration was only 16 weeks, and 29% of patients in the exenatide group and 14% of patients in the placebo group did not complete the study. Only patients who tolerated placebo injections during a 2-week “run-in” period were studied.

What are the implications of the study?

Adding exenatide to TZD treatment improves blood sugar control and reduces body weight by small amounts and also causes some nausea and vomiting.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general jounals
BMJ 2010;341:c5893-c1494.

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy This Article

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Register Now for a free account
Advertisement

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles
Update in Endocrinology: Evidence Published in 2012
Ann Intern Med. Published online 11 April 2013
In the Clinic
Type 2 Diabetes
Ann Intern Med. 2010;152(5):ITC3-1.
Diabetic Ketoacidosis
Ann Intern Med. 2010;152(1):ITC1-1.
Chronic Kidney Disease
Ann Intern Med. 2009;150(3):ITC2-1.
Peripheral Arterial Disease
Ann Intern Med. 2007;146(5):ITC3-1.
Type 2 Diabetes
Ann Intern Med. 2007;146(1):ITC1-1.
Topic Collections
PubMed Articles
Once-Weekly Exenatide: An Extended-Duration Glucagon-Like Peptide Agonist for the Treatment of Type 2 Diabetes Mellitus.
Pharmacotherapy Issue date: 2013 Apr 1
Evaluating Second-Line Treatment Options for Type 2 Diabetes: Focus on Secondary Effects of GLP-1 Agonists and DPP-4 Inhibitors.
The Annals of pharmacotherapy Issue date: 2013 Apr

Annals of Internal Medicine

Other Resources

Copyright © 2013 The American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Buy This Article

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Register Now for a free account
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)